Avalo Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Avalo Therapeutics, Inc. on December 28, 2023. The report details a material modification to the rights of security holders involving a reverse stock split of the Company's common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-240 reverse stock split, effective at 5:00 p.m. on December 28, 2023.
- Share Count Reduction: Outstanding shares decreased from approximately 192,386,419 to approximately 801,611.
- Ownership Impact: Stockholder percentage ownership and proportional voting power remain unchanged, except for minor adjustments due to rounding of fractional interests.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractions received one whole share.
- Equity Adjustments: Exercise prices and share counts for outstanding options and warrants were adjusted proportionately. The number of shares authorized under the equity incentive plan was reduced proportionately.
Outlook, Risks, and Management Commentary
The primary purpose of the reverse stock split was to enable the Company to meet the continued listing criteria for the Nasdaq Capital Market. The Company's transfer agent, Equiniti Trust Company, LLC, served as the exchange agent and issued post-split shares in book-entry form automatically.
Investor Verification Checklist
- Verify the new share count of approximately 801,611 shares outstanding.
- Confirm the adjusted exercise prices and share quantities for any held options or warrants.
- Check the Company's compliance status with Nasdaq Capital Market listing requirements post-split.
- Review the attached Certificate of Amendment (Exhibit 3.1) for specific legal terms.